Regeneron-Sanofi’s Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With…